MEK Inhibitor Benzothiazole Polymorphs for Stability and Purity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The amorphous form of the benzothiazole compound 4-fluoro-5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,3-benzothiazole-6-carboxamide (compound 1) exhibits poor stability, hygroscopicity, and is prone to photodegradation, affecting its purity and storage stability, making it unsuitable for pharmaceutical applications.
Innovation Solution
Development of seven crystalline forms of compound 1, specifically crystalline forms I and IIIA, which demonstrate improved stability, mechanical stability, and reduced hygroscopicity, ensuring higher purity and stability during storage and use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous form of compound 1 is used, then ease of manufacture is improved, but stability and storage stability deteriorate
Solution Approach 1:
The patent applies parameter changes by transforming the physical state of compound 1 from amorphous to crystalline form. This phase transition fundamentally alters the molecular arrangement and intermolecular forces, resulting in improved stability, reduced hygroscopicity, and enhanced storage stability while maintaining manufacturability through controlled crystallization processes.
Solution Approach 2:
The invention directly utilizes phase transitions by converting the amorphous compound 1 into a crystalline polymorph form. The crystalline structure provides a more stable energy state with defined melting points and reduced molecular mobility, thereby improving stability and storage characteristics compared to the amorphous form.
2Ease of manufacture
If amorphous form of compound 1 is used, then ease of manufacture is improved, but purity control deteriorates
Solution Approach 1:
By changing the physical state from amorphous to crystalline, the patent enables better purity control through the inherent properties of crystalline materials. Crystallization processes allow for selective incorporation of the desired compound into the crystal lattice while excluding impurities, resulting in higher purity products with more consistent quality.
3Reliability
If crystalline form is developed, then stability and purity control are improved, but device complexity increases
Solution Approach 1:
The patent resolves the complexity issue by optimizing the crystallization process parameters to achieve stable, reproducible crystalline forms. By establishing well-defined crystallization conditions (solvent selection, temperature profiles, addition rates), the process maintains simplicity while delivering the stability and purity benefits of the crystalline form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms I and IIIA maintain stability under various conditions, including temperature and humidity, and exhibit better solubility and dissolution profiles, providing a stable pharmaceutical form with reduced impurity formation and improved pharmacokinetic properties.
Implementation Method 1
The invention provides seven crystalline forms of compound 1, namely, crystalline form I, crystalline form II, crystalline form IIIA, crystalline form IIIB, crystalline form IV, crystalline form V and VI
Implementation Method 2
DVS results show that crystalline form I and crystalline form IIIA have almost no hygroscopicity
Implementation Method 3
The results of light stability showed that the purity of crystalline form I was significantly higher than that of crystalline form IIIA, crystalline form V and amorphous under the condition of white light
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a polymorph of a benzothiazole compound as a protein kinase Mek inhibitor, and a preparation method therefor and the medical use thereof.